Clearly, investing in individual Biotech names involved in FDA Phase II or Phase III trials is not a new concept for portfolio managers and even retail investors, but it can often be somewhat of a crapshoot and expose the investor to a high degree of specific individual security risk given the historical volatility exhibited by such names and the potential for failure during the aforementioned trials. At the moment we see the following names weighted the heaviest in the index, with none of these stocks being household names: 1) GEVA (6.83%), 2) BLUE (5.48%), 3) SGEN (4.62%), 4) RCPT (4.42%), and 5) AKRX (4.28%).
ALPS Medical Breakthroughs ETF
For more information on Street One ETF market commentary and ETF trade execution/liquidity services, contact Paul Weisbruch at [email protected]
Street One Financial is an educational/research firm utilizing the Broker Dealer services of Precision Securities, a FINRA registered Broker/Dealer.